Skip to main content
Fig. 2 | BMC Musculoskeletal Disorders

Fig. 2

From: Impact of tanezumab on health status, non-work activities and work productivity in adults with moderate-to-severe osteoarthritis

Fig. 2

EQ-5D-5L responses at baseline and week 16. Observed data. All patients completed the EQ-5D-5L. Statistical analysis of dimension responses was not conducted. Sample sizes at baseline: n = 513 (placebo), n = 513 (tanezumab 2.5 mg), n = 517 (tanezumab 5 mg). Sample sizes at week 16: n = 453 (placebo), n = 481 (tanezumab 2.5 mg), n = 482 (tanezumab 5 mg)

Back to article page

BMC Musculoskeletal Disorders

ISSN: 1471-2474

Contact us